Piper Sandler Bullish on Stryker, Sees 17% Upside Fueled by New Robotic Tech
Analyst Matthew O'Brien reaffirms an Overweight rating and $420 price target for Stryker, highlighting the potential of its new Mako RPS handheld orthopedic robot to capture cost-sensitive markets and compete with rivals like Zimmer Biomet.